Ares Financial Consulting
PRAX icon

Ares Financial Consulting’s Praxis Precision Medicines PRAX Stock Holding History

Ares Financial Consulting’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.79K Hold
13
– – ﹤0.01% 758
2026
Q2 		$4.35K Buy
+13
New +$4.12K ﹤0.01% 744

Other funds holding PRAX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Emerald Mutual Fund Advisers Trust
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

Ares Financial Consulting's PRAX Position: Q3 2026 in Review

Ares Financial Consulting held its Praxis Precision Medicines (PRAX) position steady in Q3 2026 at 13 shares worth $3.79K. The position accounts for ﹤0.01% of the portfolio, ranked #758.

Ares Financial Consulting first reported a position in PRAX in Q2 2026 and has held it in 2 quarters since. The position peaked at $4.35K in Q2 2026. 153 funds tracked by Wall St. Rank hold PRAX as of Q3 2026.

  • Ares Financial Consulting held 13 shares of Praxis Precision Medicines worth $3.79K as of Q3 2026.
  • Ares Financial Consulting left its Praxis Precision Medicines share count unchanged in Q3 2026.
  • Praxis Precision Medicines made up ﹤0.01% of Ares Financial Consulting's portfolio in Q3 2026, its #758 holding.
  • Ares Financial Consulting first reported a position in Praxis Precision Medicines in Q2 2026 and has held it in 2 quarters since.
  • Ares Financial Consulting's Praxis Precision Medicines position peaked at $4.35K in Q2 2026.
  • 153 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.